Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma

Lysosomal sequestration of anti-cancer compounds reduces drug availability at intracellular target sites, thereby limiting drug-sensitivity and inducing chemoresistance. For hepatocellular carcinoma (HCC), sorafenib (SF) is the first line systemic treatment, as well as a simultaneous activator of au...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavini, Jacopo, Dommann, Noëlle, Jakob, Manuel O., Keogh, Adrian, Bouchez, Laure C., Karkampouna, Sofia, Julio, Marianna Kruithof-de, Medova, Michaela, Zimmer, Yitzhak, Schläfli, Anna M., Tschan, Mario P., Candinas, Daniel, Stroka, Deborah, Banz, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776510/
https://www.ncbi.nlm.nih.gov/pubmed/31582741
http://dx.doi.org/10.1038/s41419-019-1989-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776510/
https://www.ncbi.nlm.nih.gov/pubmed/31582741
http://dx.doi.org/10.1038/s41419-019-1989-z

Ejemplares similares